In Brief: Semglee - A New Insulin Glargine for Diabetes

Date: January 25, 2021
Issue #: 
1616Summary: 
The FDA has approvedSemglee (Mylan), an insulin
glargine product similar toLantus, for treatment of
type 1 diabetes in children and adults and type 2
diabetes in adults.Semglee is the second " follow-on "
insulin glargine product to become available in
the US;Basaglar, which is also similar toLantus, was
the first.Lantus is a recombinant analog of human
insulin that forms microprecipitates in subcutaneous
tissue, prolonging its duration of action to a mean of
about 24 hours with no pronounced peak effect.

Source: The Medical Letter - January 5, 2021 Category: Drugs & Pharmacology Authors: admin Tags: Basaglar glargine insulin Lantus Semglee type 1 diabetes type 2 diabetes Source Type: research